Skip to main content
. 2003 Sep;15(9):2020–2031. doi: 10.1105/tpc.011775

Table 2.

List of the PCR-Based Molecular Markers Developed in This Study

Marker Primer Pairsa Fragment Sizeb Restriction Enzyme
36N13f F, 5′-AATCTTCTCTTACTCCACTCGC-3′; R, 5′-ATGGGAACTACTGACTAAACCG-3′ C = 489, b = 0
57M10r F, 5′-AGGAACAGATGGAATCTCAGG-3′; R, 5′-TGTCTCCTGTCCCAAACTAGC-3′ C = 340, b = 0
52G19f F, 5′-GCACGCATTTAAGAAGCAGG-3′; R, 5′-TTATATGACCGTATGGCAGG-3′ 502 MnlI
P1 F, 5′-TTGCGTATGTCTGTCAACTGC-3′; R, 5′-TTCCAACATCTGAACCCTCG-3′ C = 1580, b = 0
P2 F, 5′-GTTGCTCATCGTCACCATCG-3′; R, 5′-AGGTATAGAGCGAGCGGTAGC-3′ 1037 NsiI
P3 F, 5′-GGTAGTTGAAGTTTGTGATGGC-3′; R, 5′-ATGCTCTCTCCTCGCTCTGC-3′ 1110 BstNI
P4 F, 5′-TACTACAACGACCTGCTTATGG-3′ R, 5′-TGGAGAGCAGTGTAGGTAGGG-3′ 828 FokI
P5 F, 5′-AGCAGCAGTAGTCGCAGTCG-3′; R, 5′-AACATAGCCATCTGGGGTCC-3′ 1762 MnlI
P6 F, 5′-TAGAAACCAGGGTCAAGTAGGC-3′; R, 5′-GCTGAGTTTGAGGTCGGTGG-3′ 1470 MseI
P7 F, 5′-AGTGCCTCATCTATCGCTTCG-3′; R, 5′-GTTCCACAAACCGATCTAGCG-3′ 2046 ScaI
a

F, forward primer; R, reverse primer.

b

Numbers indicate the size (in bp) of amplified fragments. b, bc1-2 mutant; C, C-Bao.

HHS Vulnerability Disclosure